Dopamine Depletion Does Not Protect Against Acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Toxicity in Vivo

Overview

Journal J Neurosci

Specialty Neurology

Date 2005 Oct 14

PMID 16221852

Citations 12

Authors

Daphne M Hasbani

Francisco A Perez

Richard D Palmiter

Karen L OMalley

Affiliations

Soon will be listed here.

Abstract

Dopamine (DA) has been postulated to play a role in the loss of dopaminergic substantia nigra (SN) neurons in Parkinson's disease because of its propensity to oxidize and form quinones and other reactive oxygen species that can alter cellular function. Moreover, DA depletion can attenuate dopaminergic cell loss in vitro. To test the contribution of DA to SN impairment in vivo, we used DA-deficient mice, which lack the enzyme tyrosine hydroxylase in dopaminergic cells, and mice pharmacologically depleted of DA by alpha-methyl-p-tyrosine pretreatment. Mice were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxin that produces parkinsonian pathology in humans, nonhuman primates, and rodents. In contrast to in vitro results, genetic or pharmacologic DA depletion did not attenuate loss of dopaminergic neurons in the SN or dopaminergic neuron terminals in the striatum. These results suggest that DA does not contribute to acute MPTP toxicity in vivo.

Citing Articles

New insights in animal models of neurotoxicity-induced neurodegeneration.

Sanfeliu C, Bartra C, Sunol C, Rodriguez-Farre E Front Neurosci. 2024; 17:1248727.

PMID: 38260026 PMC: 10800989. DOI: 10.3389/fnins.2023.1248727.

α-Synuclein-Dependent Calcium Entry Underlies Differential Sensitivity of Cultured SN and VTA Dopaminergic Neurons to a Parkinsonian Neurotoxin.

Lieberman O, Choi S, Kanter E, Saverchenko A, Frier M, Fiore G eNeuro. 2017; 4(6).

PMID: 29177188 PMC: 5701296. DOI: 10.1523/ENEURO.0167-17.2017.

Changes in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure.

Choi S, Panhelainen A, Schmitz Y, Larsen K, Kanter E, Wu M J Biol Chem. 2015; 290(11):6799-809.

PMID: 25596531 PMC: 4358106. DOI: 10.1074/jbc.M114.631556.

MPP+-induces PUMA- and p53-dependent, but ATF3-independent cell death.

Bernstein A, OMalley K Toxicol Lett. 2013; 219(2):93-8.

PMID: 23500530 PMC: 3652523. DOI: 10.1016/j.toxlet.2013.03.003.

Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Cho K, Searle K, Webb M, Yi H, Ferreira P Cell Mol Life Sci. 2012; 69(20):3511-27.

PMID: 22821000 PMC: 3445802. DOI: 10.1007/s00018-012-1071-9.

References

Stokes A, Hastings T, Vrana K . Cytotoxic and genotoxic potential of dopamine. J Neurosci Res. 1999; 55(6):659-65. DOI: 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C. View

Berman S, Hastings T . Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem. 1999; 73(3):1127-37. DOI: 10.1046/j.1471-4159.1999.0731127.x. View

Kuhn D, Arthur Jr R, Thomas D, Elferink L . Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J Neurochem. 1999; 73(3):1309-17. DOI: 10.1046/j.1471-4159.1999.0731309.x. View

Donovan D, Miner L, Perry M, Revay R, SHARPE L, Przedborski S . Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Brain Res Mol Brain Res. 1999; 73(1-2):37-49. DOI: 10.1016/s0169-328x(99)00235-1. View

Kim D, Szczypka M, Palmiter R . Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J Neurosci. 2000; 20(12):4405-13. PMC: 6772455. View

Lotharius J, OMalley K . The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem. 2000; 275(49):38581-8. DOI: 10.1074/jbc.M005385200. View

Rabinovic A, Lewis D, Hastings T . Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience. 2000; 101(1):67-76. DOI: 10.1016/s0306-4522(00)00293-1. View

Betarbet R, Sherer T, MacKenzie G, Panov A, Greenamyre J . Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000; 3(12):1301-6. DOI: 10.1038/81834. View

Greenamyre J . Glutamatergic influences on the basal ganglia. Clin Neuropharmacol. 2001; 24(2):65-70. DOI: 10.1097/00002826-200103000-00001. View

10.

Blum D, Torch S, Lambeng N, Nissou M, Benabid A, Sadoul R . Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol. 2001; 65(2):135-72. DOI: 10.1016/s0301-0082(01)00003-x. View

11.

Vila M, Jackson-Lewis V, Guegan C, Wu D, Teismann P, Choi D . The role of glial cells in Parkinson's disease. Curr Opin Neurol. 2001; 14(4):483-9. DOI: 10.1097/00019052-200108000-00009. View

12.

Chartoff E, Marck B, Matsumoto A, Dorsa D, Palmiter R . Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc Natl Acad Sci U S A. 2001; 98(18):10451-6. PMC: 56981. DOI: 10.1073/pnas.181356498. View

13.

Dryhurst G . Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders?. Adv Exp Med Biol. 2002; 500:373-96. DOI: 10.1007/978-1-4615-0667-6_61. View

14.

Wu D, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C . Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 2002; 22(5):1763-71. PMC: 6758858. View

15.

Alam M, Schmidt W . Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res. 2002; 136(1):317-24. DOI: 10.1016/s0166-4328(02)00180-8. View

16.

Sherer T, Kim J, Betarbet R, Greenamyre J . Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol. 2002; 179(1):9-16. DOI: 10.1006/exnr.2002.8072. View

17.

Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Busceti C . Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci. 2003; 23(26):8955-66. PMC: 6740387. View

18.

Mortensen O, Amara S . Dynamic regulation of the dopamine transporter. Eur J Pharmacol. 2003; 479(1-3):159-70. DOI: 10.1016/j.ejphar.2003.08.066. View

19.

Zimprich A, Muller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M . The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet. 2003; 74(1):11-9. PMC: 1181898. DOI: 10.1086/380647. View

20.

Vila M, Przedborski S . Genetic clues to the pathogenesis of Parkinson's disease. Nat Med. 2004; 10 Suppl:S58-62. DOI: 10.1038/nm1068. View